Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat PK/PD in Pediatric and Adult Patients with Hematological Malignancies
NCT03605212Phase 2Terminated
- Sponsor
- Menarini Group
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of febuxostat in tumor lysis syndrome (TLS) (5 arms), sponsored by Menarini Group. Primary endpoints: Apparent Clearance at 7 days, Apparent Volume of Distribution at 7 days and 4 more. Started Feb 2017; status: terminated.
02
Drugs
febuxostat
03
Conditions
tumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT03605212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605212.